Korea Investment CORP Sells 42,200 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Korea Investment CORP reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 61.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 26,304 shares of the medical research company’s stock after selling 42,200 shares during the period. Korea Investment CORP owned about 0.05% of Charles River Laboratories International worth $4,856,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the period. Tortoise Investment Management LLC lifted its holdings in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after buying an additional 115 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in Charles River Laboratories International in the 4th quarter valued at about $56,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International in the 3rd quarter worth about $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster bought 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 3.2 %

Shares of NYSE:CRL opened at $150.58 on Tuesday. The business’s 50-day moving average is $164.43 and its 200 day moving average is $182.29. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1 year low of $146.64 and a 1 year high of $273.32. The firm has a market capitalization of $7.70 billion, a P/E ratio of 1,003.89, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. During the same period last year, the firm posted $2.46 EPS. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRL. Robert W. Baird lowered their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research note on Monday, March 3rd. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Morgan Stanley reduced their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).